Literature DB >> 36090463

Statistical inference of adaptive type II progressive hybrid censored data with dependent competing risks under bivariate exponential distribution.

Yuge Du1, Wenhao Gui1.   

Abstract

Marshall-Olkin bivariate exponential distribution is used to statistically infer the adaptive type II progressive hybrid censored data under dependent competition risk model. For complex censored data with only partial failure reasons observed, maximum likelihood estimation and approximate confidence interval based on Fisher information are established. At the same time, Bayesian estimation is performed under the highly flexible Gamma-Dirichlet prior distribution and the highest posterior density interval using Gibbs sampling and Metropolis-Hastings algorithm is obtained. Then the performance of two methods is compared through several indexes. In addition, the Monte Carlo method is used for data simulation of multiple sets of variables to give experimental suggestions. Finally, a practical example is given to illustrate the operability and applicability of the proposed algorithm to efficiently carry out reliability test.
© 2021 Informa UK Limited, trading as Taylor & Francis Group.

Entities:  

Keywords:  Bayesian estimation; Dependent competing risks; Gamma–Dirichlet prior; adaptive type II progressive hybrid censored data; bivariate exponential distribution

Year:  2021        PMID: 36090463      PMCID: PMC9451543          DOI: 10.1080/02664763.2021.1937961

Source DB:  PubMed          Journal:  J Appl Stat        ISSN: 0266-4763            Impact factor:   1.416


  2 in total

1.  A nonidentifiability aspect of the problem of competing risks.

Authors:  A Tsiatis
Journal:  Proc Natl Acad Sci U S A       Date:  1975-01       Impact factor: 11.205

2.  A Proportional Hazards Regression Model for the Sub-distribution with Covariates Adjusted Censoring Weight for Competing Risks Data.

Authors:  Peng He; Frank Eriksson; Thomas H Scheike; Mei-Jie Zhang
Journal:  Scand Stat Theory Appl       Date:  2015-06-05       Impact factor: 1.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.